Nonclinical Animal Dose Escalation Studies (Schedule 1 Chemicals)

This contract involves the execution of nonclinical dose escalation studies using highly hazardous chemical agents, such as phosphine and cyanide, in animal models. The primary goal is to evaluate the efficacy of medical countermeasures under the FDA’s Animal Rule, which allows for drug approval based on animal testing when human trials are not ethical or feasible. The work focuses on Schedule 1 chemicals, requiring strict adherence to safety and regulatory standards due to the high-risk nature of the substances involved. The contract is a subcontract under the Department of Health and Human Services, specifically managed by the Biomedical Advanced Research and Development Authority (BARDA) along with associated offices. It falls under the NAICS code 541714, which covers research and development in biotechnology. While specific details about the location of performance and points of contact are not provided, the contract supports the development of critical medical countermeasures aimed at protecting public health from chemical threats.